By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

AstraZeneca scrapped a £450m vaccine plant in Liverpool after the UK government missed a critical funding deadline. The ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

(Reuters) -Drugmaker AstraZeneca has agreed to buy biotechnology company EsoBiotec for up to $1 billion, it said on Monday, ...

AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all ...

AstraZeneca has agreed to purchase Belgium-based EsoBiotec for up to $1 billion. The acquisition is aimed at enhancing ...

The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on ...